logo
Plus   Neg
Share
Email

UBX To Report Phase I Data In Q1, NVTA On Watch, NTGN Faces Busy Year Ahead

pharma-031417_19sep18-lt.jpg

The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. Unity Biotechnology Inc. (UBX)

Lost 13.50% to close Wednesday's (Sep.19) trading at $17.05.

News: No news

Clinical Trials & Near-term Catalysts:

A phase I clinical trial evaluating UBX0101 in moderate to severe osteoarthritis of the knee is underway. Initial results from this study are expected in the first quarter of next year.

Recent event:

On May 3, 2018, the Company went public on the Nasdaq Global Select Market, offering its shares at a price of $17 each.

2. Xenetic Biosciences Inc. (XBIO)

Lost 12.86% to close Wednesday's trading at $2.10.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase II clinical trial evaluating MABp1 (Bermekimab) in patients with moderate to severe Atopic Dermatitis is underway.
-- A phase II clinical study evaluating Bermekimab in patients with moderate to severe Hidradenitis Suppurativa is underway.
-- A physician-sponsored clinical research study being conducted to examine the safety of Bermekimab in combination with Onivyde and 5- fluorouracil (5FU)/folinic acid (leucovorin) for pancreatic cancer patients suffering from cachexia is ongoing. Clinical results from this study are expected to be reported later in 2018.

3. Invitae Corp. (NVTA)

Lost 11.96% to close Wednesday's trading at $16.12.

News: No news

Recent event:

On August 7, the Company reported financial and operating results for the second quarter ended June 30, 2018.

Net loss for the recent second quarter was $31.67 million or $0.47 per share compared to a net loss of $28.56 million or $0.66 per share in the year-ago quarter. Total revenue in the second quarter of 2018 soared to $37.3 million from $14.33 million in the year-earlier quarter.

Following strong quarterly performance, the Company raised its 2018 annual revenue guidance from more than $130 million to between $135 and $140 million. Annual revenue in 2017 was $68.22 million.

4. Neon Therapeutics Inc. (NTGN)

Lost 10.44% to close Wednesday's trading at $7.81.

News: No news

Recent event:

The Company's shares debuted on The Nasdaq Global Select Market on June 27, 2018, at an offering price of $16.00 each.

Near-term Catalysts:

Neon is a clinical-stage immuno-oncology company developing neoantigen-targeted therapies.

-- A phase 1b clinical trial of NEO-PV-01 in the metastatic setting, dubbed NT-001, has completed enrollment, with updated data expected to be presented in October 2018 at ESMO, and 52-week data expected in the first half of 2019.
-- Initiation of phase 1b clinical trial of NEO-PV-01 in metastatic melanoma combinations, dubbed NT-003, is expected in the second half of 2018.
-- The 52-week data from a phase Ib trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer, dubbed NT-002, is expected in the second half of 2019.
-- Submission of a European Clinical Trial Application (CTA) for NEO-PTC-01, a personal neoantigen T-cell therapy, in the first half of 2019.
-- Submission of an Investigational New Drug (IND) application for NEO-SV-01 in subset of ER+ breast cancer to the FDA in the first half of 2019.

5. Xeris Pharmaceuticals Inc. (XERS)

Lost 9.63% to close Wednesday's trading at $21.49.

News: No news

Recent events:

-- On June 21, 2018, the Company went public on the Nasdaq Global Select Market, offering its shares at a price of $15.00 each.
-- On August 13, the Company announced financial results for the second quarter and provided corporate highlights.

Xeris has submitted the NDA for its lead product candidate, Glucagon Rescue Pen, for the treatment of severe hypoglycemia, a potentially life-threatening condition, in people with diabetes.

-- On August 17, the Company announced that Jessica Castle, M.D., an associate professor of medicine in the OHSU School of Medicine and OHSU Harold Schnitzer Diabetes Health Center in Portland, Oregon, is conducting a phase I clinical trial with a dual-hormone artificial pancreas using Xeris' ready-to-use liquid glucagon to test the efficacy of a new closed-loop algorithm for managing blood glucose in people with Type 1 Diabetes before and after exercise. Results from this study are expected in the first half of 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT